Walleye Capital
ATXS

Walleye Capital’s Astria Therapeutics ATXS Stock Holding History

Walleye Capital’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,439
Closed -$25K – 4552
2025
Q3 		$25K Sell
3,439
-98,910
-97% -$669K ﹤0.01% 4172
2025
Q2 		$549K Buy
102,349
+2,242
+2% +$10.9K ﹤0.01% 2567
2025
Q1 		$535K Sell
100,107
-45,295
-31% -$317K ﹤0.01% 2503
2024
Q4 		$1.3M Sell
145,402
-29,179
-17% -$310K ﹤0.01% 2153
2024
Q3 		$1.92M Buy
174,581
+68,939
+65% +$767K ﹤0.01% 1987
2024
Q2 		$961K Buy
105,642
+92,699
+716% +$905K ﹤0.01% 2892
2024
Q1 		$182K Buy
+12,943
New +$161K ﹤0.01% 4043
2023
Q4 		– Sell
-19,530
Closed -$146K – 4923
2023
Q3 		$146K Buy
+19,530
New +$167K ﹤0.01% 3750

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's ATXS Position: Q4 2025 in Review

Walleye Capital sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 3,439 shares — an estimated $25K sold.

Walleye Capital first reported a position in ATXS in Q3 2023 and held it in 8 quarters. The position peaked at $1.92M in Q3 2024. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

  • Walleye Capital reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 3,439 Astria Therapeutics shares in Q4 2025, an estimated $25K.
  • Walleye Capital first reported a position in Astria Therapeutics in Q3 2023 and held it in 8 quarters.
  • Walleye Capital's Astria Therapeutics position peaked at $1.92M in Q3 2024.
  • 141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.